{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:19:29Z","timestamp":1782188369415,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multiple sclerosis (MS) is a chronic immune-mediated disease that can cause severe physical and cognitive disability. While modern therapies have improved outcomes in relapsing MS, patients with advanced disease remain underserved. In this stage, neurodegeneration dominates, treatment options are limited, and care becomes complex. Yet individuals with advanced MS are largely absent from trials, registries, and structured care pathways, leaving a major evidence gap.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To characterize the clinical, social, and treatment-related profile of patients with advanced MS in institutional care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted an exploratory, retrospective study of patients with advanced MS (EDSS\u2009\u2265\u20096.5) admitted to a long-term care facility in Vienna. Data on disease history, comorbidities, medications, cognitive and functional status, and social background were extracted from medical records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty-four patients were included (73.5% female; median age at admission: 54.1\u00a0years). Most had secondary progressive MS (85.3%). Disease-modifying therapy (DMT) exposure was limited; only one patient received DMT during care. Comorbidity and polypharmacy were frequent. EDSS progression occurred in 50%. The Braden Scale was the only score differing significantly between cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study highlights care gaps in advanced MS and the need for tailored strategies in institutional care settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13296-6","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:57:16Z","timestamp":1754197036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced multiple sclerosis: an exploratory study on a neglected patient population"],"prefix":"10.1007","volume":"272","author":[{"given":"Omar","family":"Keritam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ascoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Harsanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Unseld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-6647","authenticated-orcid":false,"given":"Paulus Stefan","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,3]]},"reference":[{"issue":"2","key":"13296_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"key":"13296_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.654284","volume":"15","author":"MW Psenicka","year":"2021","unstructured":"Psenicka MW, Smith BC, Tinkey RA, Williams JL (2021) Connecting neuroinflammation and neurodegeneration in multiple sclerosis: are oligodendrocyte precursor cells a nexus of disease? Front Cell Neurosci 15:654284. https:\/\/doi.org\/10.3389\/fncel.2021.654284","journal-title":"Front Cell Neurosci"},{"key":"13296_CR3","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3389\/fimmu.2019.01564","volume":"10","author":"PS Rommer","year":"2019","unstructured":"Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L et al (2019) Immunological aspects of approved MS therapeutics. Front Immunol 10:1564. https:\/\/doi.org\/10.3389\/fimmu.2019.01564","journal-title":"Front Immunol"},{"issue":"2","key":"13296_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A et al (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175\u2013187. https:\/\/doi.org\/10.1001\/jama.2018.20588","journal-title":"JAMA"},{"issue":"9","key":"13296_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaneurol.2022.1929","volume":"79","author":"E Portaccio","year":"2022","unstructured":"Portaccio E, Fonderico M, Iaffaldano P, Pasto L, Razzolini L, Bellinvia A et al (2022) Disease-modifying treatments and time to loss of ambulatory function in patients with primary progressive multiple sclerosis. JAMA Neurol 79(9):869\u2013878. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1929","journal-title":"JAMA Neurol"},{"issue":"6","key":"13296_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2174\/1381612827666210920151231","volume":"28","author":"P Rommer","year":"2022","unstructured":"Rommer P, Zettl UK (2022) Treatment options in multiple sclerosis and neuromyelitis optica spectrum disorders. Curr Pharm Des 28(6):428\u2013436. https:\/\/doi.org\/10.2174\/1381612827666210920151231","journal-title":"Curr Pharm Des"},{"key":"13296_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","volume":"12","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H et al (2017) Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord 12:70\u201378. https:\/\/doi.org\/10.1016\/j.msard.2017.01.007","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"13296_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8(11):647\u2013656. https:\/\/doi.org\/10.1038\/nrneurol.2012.168","journal-title":"Nat Rev Neurol"},{"key":"13296_CR9","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 9:3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116","journal-title":"Front Immunol"},{"issue":"Pt 5","key":"13296_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(Pt 5):1175\u20131189. https:\/\/doi.org\/10.1093\/brain\/awp070","journal-title":"Brain"},{"issue":"8","key":"13296_CR11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/ene.14248","volume":"27","author":"A Solari","year":"2020","unstructured":"Solari A, Giordano A, Sastre-Garriga J, Kopke S, Rahn AC, Kleiter I et al (2020) EAN guideline on palliative care of people with severe, progressive multiple sclerosis. Eur J Neurol 27(8):1510\u20131529. https:\/\/doi.org\/10.1111\/ene.14248","journal-title":"Eur J Neurol"},{"issue":"1","key":"13296_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08870440903287934","volume":"26","author":"C Bowen","year":"2011","unstructured":"Bowen C, MacLehose A, Beaumont JG (2011) Advanced multiple sclerosis and the psychosocial impact on families. Psychol Health 26(1):113\u2013127. https:\/\/doi.org\/10.1080\/08870440903287934","journal-title":"Psychol Health"},{"issue":"5","key":"13296_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ane.12631","volume":"135","author":"OM Ronning","year":"2017","unstructured":"Ronning OM, Tornes KD (2017) Need for symptomatic management in advanced multiple sclerosis. Acta Neurol Scand 135(5):529\u2013532. https:\/\/doi.org\/10.1111\/ane.12631","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"13296_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/apm-23-455","volume":"13","author":"D Murteira","year":"2024","unstructured":"Murteira D, Rego F (2024) Integrating palliative care in patients with advanced multiple sclerosis: a scoping review. Ann Palliat Med 13(2):386\u2013396. https:\/\/doi.org\/10.21037\/apm-23-455","journal-title":"Ann Palliat Med"},{"key":"13296_CR15","doi-asserted-by":"publisher","first-page":"1379538","DOI":"10.3389\/fimmu.2024.1379538","volume":"15","author":"O Fernandez","year":"2024","unstructured":"Fernandez O, Sorensen PS, Comi G, Vermersch P, Hartung HP, Leocani L et al (2024) Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review. Front Immunol 15:1379538. https:\/\/doi.org\/10.3389\/fimmu.2024.1379538","journal-title":"Front Immunol"},{"issue":"2_suppl","key":"13296_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1352458517708099","volume":"23","author":"T Berger","year":"2017","unstructured":"Berger T, Kobelt G, Berg J, Capsa D, Gannedahl M, European Multiple Sclerosis P (2017) New insights into the burden and costs of multiple sclerosis in Europe: results for Austria. Mult Scler 23(2_suppl):17\u201328. https:\/\/doi.org\/10.1177\/1352458517708099","journal-title":"Mult Scler"},{"issue":"8","key":"13296_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1474-4422(10)70135-6","volume":"9","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Horwitz RI (2010) Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 9(8):820\u2013828. https:\/\/doi.org\/10.1016\/S1474-4422(10)70135-6","journal-title":"Lancet Neurol"},{"key":"13296_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123156","volume":"464","author":"TR Wicks","year":"2024","unstructured":"Wicks TR, Jakimovski D, Reeves J, Bergsland N, Dwyer MG, Weinstock-Guttman B et al (2024) Comorbid onset of cardiovascular diagnosis and long-term confirmed disability progression in multiple sclerosis: a 15-year follow-up study. J Neurol Sci 464:123156. https:\/\/doi.org\/10.1016\/j.jns.2024.123156","journal-title":"J Neurol Sci"},{"key":"13296_CR19","doi-asserted-by":"publisher","first-page":"1330066","DOI":"10.3389\/fneur.2023.1330066","volume":"14","author":"F Bruggemann","year":"2023","unstructured":"Bruggemann F, Gross S, Susse M, Hok P, Strauss S, Ziemssen T et al (2023) Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units. Front Neurol 14:1330066. https:\/\/doi.org\/10.3389\/fneur.2023.1330066","journal-title":"Front Neurol"},{"issue":"12","key":"13296_CR20","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1177\/1352458520985118","volume":"27","author":"KO Jalusic","year":"2021","unstructured":"Jalusic KO, Ellenberger D, Rommer P, Stahmann A, Zettl U, Berger K (2021) Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care. Mult Scler 27(12):1852\u20131863. https:\/\/doi.org\/10.1177\/1352458520985118","journal-title":"Mult Scler"},{"issue":"6","key":"13296_CR21","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00415-024-12286-4","volume":"271","author":"Y Goereci","year":"2024","unstructured":"Goereci Y, Ellenberger D, Rommer P, Dunkl V, Golla H, Zettl U et al (2024) Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry. J Neurol 271(6):3409\u20133416. https:\/\/doi.org\/10.1007\/s00415-024-12286-4","journal-title":"J Neurol"},{"issue":"2","key":"13296_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00415-023-12099-x","volume":"271","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Kavak KS, Coyle PK, Goodman AD, Gottesman M, Zivadinov R et al (2024) Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS consortium. J Neurol 271(2):711\u2013722. https:\/\/doi.org\/10.1007\/s00415-023-12099-x","journal-title":"J Neurol"},{"key":"13296_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103406","volume":"57","author":"D Jakimovski","year":"2022","unstructured":"Jakimovski D, Kavak KS, Vaughn CB, Goodman AD, Coyle PK, Krupp L et al (2022) Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Mult Scler Relat Disord 57:103406. https:\/\/doi.org\/10.1016\/j.msard.2021.103406","journal-title":"Mult Scler Relat Disord"},{"key":"13296_CR24","doi-asserted-by":"publisher","first-page":"1295770","DOI":"10.3389\/fneur.2024.1295770","volume":"15","author":"X Wu","year":"2024","unstructured":"Wu X, Wang S, Xue T, Tan X, Li J, Chen Z et al (2024) Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials. Front Neurol 15:1295770. https:\/\/doi.org\/10.3389\/fneur.2024.1295770","journal-title":"Front Neurol"},{"issue":"1","key":"13296_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ane.12673","volume":"136","author":"PS Rommer","year":"2017","unstructured":"Rommer PS, Suhnel A, Konig N, Zettl UK (2017) Coping with multiple sclerosis-the role of social support. Acta Neurol Scand 136(1):11\u201316. https:\/\/doi.org\/10.1111\/ane.12673","journal-title":"Acta Neurol Scand"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13296-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13296-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13296-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T02:41:54Z","timestamp":1756608114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13296-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13296"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13296-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no other conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the ethics committee of the Medical University of Vienna (EK No. 1117\/2024) in December 2023. Informed consent was obtained from patients, from whom additional historical information was collected via a case report form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and patient consent"}},{"value":"Oliver Ascoli collected the data for his diploma thesis as part of this project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Additional information"}}],"article-number":"553"}}